Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pancreas

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MPA.0000000000000394PMID 26355551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How I treat older patients with ALL.

  2013cited by this paper
• S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

  2013cited by this paper
• A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma

  2013cited by this paper
• Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

  2012cited by this paper
• Pancreatic Tumor Sensitivity to Plasma L-Asparagine Starvation

  2012cited by this paper
• Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trial

  2011cited by this paper
• CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

  2010cited by this paper
• Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype

  2010cited by this paper
• Finding value in the U.S. Food and Drug Administration's Fast Track program.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Asparagine synthetase: a new potential biomarker in ovarian cancer.

  2009cited by this paper
• Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines

  2008cited by this paper
• Expression profiling of PC‐3 cell line variants and comparison of MIC‐1 transcript levels in benign and malignant prostate

  2007cited by this paper
• Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

  2007cited by this paper
• Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin.

  2007cited by this paper
• Experimental designs for phase I and phase I/II dose-finding studies

  2006cited by this paper
• Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.

  2006cited by this paper
• Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells

  2006cited by this paper
• 160 POSTER In vitro and in vivo evaluation of pegaspargase for the treatment of solid tumors and lymphomas

  2006cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK).

  2005cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

  2005cited by this paper
• Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.

  2004cited by this paper
• Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells.

  2001cited by this paper
• Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Cancer statistics

  1989cited by this paper
• Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent.

  1982cited by this paper
• Phase II study of L-asparaginase in the treatment of pancreatic carcinoma.

  1980cited by this paper
• Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase

  1978cited by this paper
• Human pancreatic carcinoma (mia paca‐2) in continuous culture: Sensitivity to asparaginase

  1977cited by this paper
• Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.

  1977cited by this paper
• The distribution of L-asparagine synthetase in the principal organs of several mammalian and avian species.

  1974cited by this paper

• Mechanistic insights into L-asparaginase resistance in cancers.

  2025cites this paper
• NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism

  2025cites this paper
• Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Exploiting pancreatic cancer metabolism: challenges and opportunities.

  2024cites this paper
• Long-acting Erwinia chrysanthemi, Pegcrisantaspase, induces alternate amino acid biosynthetic pathways in a preclinical model of pancreatic ductal adenocarcinoma

  2024cites this paper
• Engineering of Erythrocytes as Drug Carriers for Therapeutic Applications

  2024cites this paper
• CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer.

  2024cites this paper
• A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models.

  2024cites this paper
• Tailoring cell-inspired biomaterials to fuel cancer therapy

  2024cites this paper
• Artificial cells for in vivo biomedical applications through red blood cell biomimicry

  2024cites this paper
• Biochemical Markers of Tumor Cell Sensitivity to L-Asparaginase

  2023cites this paper
• Cell-nanocarrier drug delivery system: a promising strategy for cancer therapy

  2023cites this paper
• Revolutionizing cancer treatment: The power of cell-based drug delivery systems.

  2023cites this paper
• Cellular Drug Delivery System for Disease Treatment.

  2023cites this paper
• The role of amino acid metabolism alterations in pancreatic cancer: From mechanism to application.

  2023cites this paper
• l-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.

  2023cites this paper
• Erythrocyte-based Drug Delivery: How Far from Clinical Application?

  2023cites this paper
• Drug delivery systems based on blood cells

  2022cites this paper
• Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances

  2022cites this paper
• Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

  2022cites this paper
• Cell-based drug delivery systems and their in vivo fate.

  2022cites this paper
• Targeting amino acid metabolism in cancer.

  2022cites this paper
• Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

  2022cites this paper
• Microbial L-asparaginase as a promising enzyme for treatment of various cancers

  2022cites this paper
• Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy

  2022cites this paper
• Novel systemic treatment approaches for metastatic pancreatic cancer

  2022cites this paper
• Red blood cells membrane-derived nanoparticles: Applications and key challenges in their clinical translation.

  2022cites this paper
• Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.

  2021cites this paper
• L-Lysine α-Oxidase: Enzyme with Anticancer Properties

  2021cites this paper
• Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress

  2021cites this paper
• Resealed erythrocytes: Towards a novel approach for anticancer therapy

  2021cites this paper
• Harnessing the Co-vulnerabilities of Amino Acid-Restricted Cancers.

  2021cites this paper
• MAPK signaling regulates c‐MYC for melanoma cell adaptation to asparagine restriction

  2021cites this paper
• Pancreatic ductal adenocarcinoma in the era of precision medicine.

  2021cites this paper
• Asparagine Synthetase-Mediated l-Asparagine Metabolism Disorder Promotes the Perineural Invasion of Oral Squamous Cell Carcinoma

  2021cites this paper
• Novel engineering: biomimicking erythrocyte as a revolutionary platform for drugs and vaccines delivery.

  2021cites this paper
• Erythrocytes and Nanoparticles: New Therapeutic Systems

  2021cites this paper
• Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer

  2021cites this paper
• Glucose and Amino Acid Metabolic Dependencies Linked to Stemness and Metastasis in Different Aggressive Cancer Types

  2021cites this paper
• Clinical progress and advanced research of red blood cells based drug delivery system.

  2021cites this paper
• Эритроцит как идеальный носитель для внутрисосудистой доставки лекарств

  2020cites this paper
• Metabolism of pancreatic cancer: paving the way to better anticancer strategies

  2020cites this paper
• Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies

  2020cites this paper
• Erythrocytes as Carriers: From Drug Delivery to Biosensors

  2020cites this paper
• New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Erythrocytes as Carriers of Therapeutic Enzymes

  2020cites this paper
• High Expression of Asparagine Synthetase Is Associated with Poor Prognosis of Breast Cancer in Chinese Population

  2020cites this paper
• Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma

  2020cites this paper
• The role of asparagine synthetase on nutrient metabolism in pancreatic disease.

  2020cites this paper
• Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanisms

  2020cites this paper
• Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies

  2020cites this paper
• Erythrocyte-derived drug delivery systems in cancer therapy

  2020cites this paper
• The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.

  2020cites this paper
• Erythrocyte as an ideal carrier for intavascular drug delivery

  2020cites this paper
• What makes a good new therapeutic l-asparaginase?

  2019cites this paper
• Translational Reprogramming Marks Adaptation to Asparagine Restriction in Cancer

  2019cites this paper
• Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

  2019cites this paper
• Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems

  2018cites this paper
• Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

  2018cites this paper
• Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

  2018cites this paper
• Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

  2018cites this paper
• Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.

  2018cites this paper
• Enhanced stability of L-asparaginase by its bioconjugation to poly(styrene-co-maleic acid) and Ecoflex nanoparticles.

  2017cites this paper
• Erythrocyte-based drug delivery in Transfusion Medicine: Wandering questions seeking answers.

  2017cites this paper
• Near infrared fluorescent sensors and their use in vivo

  2017cites this paper
• Asparaginase pharmacology: challenges still to be faced

  2017cites this paper
• Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities.

  2017cites this paper
• Circulatory-cell-mediated nanotherapeutic approaches in disease targeting.

  2017cites this paper
• Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

  2016cites this paper
• Drug delivery with living cells.

  2016cites this paper
• Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine.

  2016cites this paper
• Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

  2016cites this paper